VolitionRx (VNRX) Competitors $0.60 +0.00 (+0.82%) Closing price 04:00 PM EasternExtended Trading$0.60 -0.01 (-0.83%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock VNRX vs. NGNE, DBVT, RAPT, ANNX, CADL, NMRA, RNAC, JBIO, TNXP, and ALLOShould you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Neurogene (NGNE), DBV Technologies (DBVT), Rapt Therapeutics (RAPT), Annexon (ANNX), Candel Therapeutics (CADL), Neumora Therapeutics (NMRA), Cartesian Therapeutics (RNAC), Jade Biosciences (JBIO), Tonix Pharmaceuticals (TNXP), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry. VolitionRx vs. Its Competitors Neurogene DBV Technologies Rapt Therapeutics Annexon Candel Therapeutics Neumora Therapeutics Cartesian Therapeutics Jade Biosciences Tonix Pharmaceuticals Allogene Therapeutics VolitionRx (NYSE:VNRX) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Is VNRX or NGNE more profitable? Neurogene has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Neurogene's return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-2,321.14% N/A -163.39% Neurogene N/A -33.33%-30.34% Which has more volatility and risk, VNRX or NGNE? VolitionRx has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Do analysts recommend VNRX or NGNE? VolitionRx currently has a consensus target price of $3.50, suggesting a potential upside of 478.51%. Neurogene has a consensus target price of $46.17, suggesting a potential upside of 159.07%. Given VolitionRx's stronger consensus rating and higher possible upside, analysts clearly believe VolitionRx is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has better earnings & valuation, VNRX or NGNE? VolitionRx has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$1.32M49.34-$35.32M-$0.25-2.42Neurogene$930K273.43-$75.14M-$4.31-4.13 Does the media favor VNRX or NGNE? In the previous week, Neurogene had 2 more articles in the media than VolitionRx. MarketBeat recorded 2 mentions for Neurogene and 0 mentions for VolitionRx. Neurogene's average media sentiment score of 0.95 beat VolitionRx's score of 0.00 indicating that Neurogene is being referred to more favorably in the news media. Company Overall Sentiment VolitionRx Neutral Neurogene Positive Do insiders and institutionals hold more shares of VNRX or NGNE? 8.1% of VolitionRx shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 10.4% of VolitionRx shares are held by insiders. Comparatively, 11.6% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryNeurogene beats VolitionRx on 9 of the 17 factors compared between the two stocks. Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNRX vs. The Competition Export to ExcelMetricVolitionRxDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$65.10M$21.95M$5.66B$21.54BDividend YieldN/AN/A5.75%3.52%P/E Ratio-1.68N/A75.7529.48Price / Sales49.3417.33560.9560.08Price / CashN/AN/A37.6024.33Price / Book-5.50N/A12.414.57Net Income-$35.32M-$19.12M$3.29B$1.00B7 Day Performance-11.03%-11.03%1.26%-0.20%1 Month Performance-8.33%-8.33%3.84%2.42%1 Year Performance6.14%6.14%61.01%13.12% VolitionRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNRXVolitionRx1.552 of 5 stars$0.61+0.8%$3.50+478.5%-2.7%$65.10M$1.32M-1.6880Positive NewsGap DownNGNENeurogene1.5982 of 5 stars$17.45-8.2%$46.17+164.6%-58.5%$271.17M$930K-4.0590DBVTDBV Technologies2.2807 of 5 stars$9.90+0.3%$14.75+49.0%+143.9%$270.39M$4.15M-2.0880Gap UpHigh Trading VolumeRAPTRapt Therapeutics3.1941 of 5 stars$17.42+7.4%$21.57+23.8%+73.7%$268.25MN/A-1.2380News CoveragePositive NewsAnalyst UpgradeGap UpANNXAnnexon2.1896 of 5 stars$2.49+2.9%$12.50+402.0%-54.5%$265.93MN/A-1.9360Positive NewsCADLCandel Therapeutics2.5564 of 5 stars$4.85+1.3%$20.00+312.4%-24.7%$262.95M$120K-7.0360Positive NewsNMRANeumora Therapeutics3.1948 of 5 stars$1.52-6.2%$7.14+369.9%-86.7%$262.35MN/A-0.97108Positive NewsHigh Trading VolumeRNACCartesian Therapeutics2.2763 of 5 stars$9.79+1.1%$40.00+308.6%-42.5%$251.70M$1.03M-0.1964Positive NewsJBIOJade Biosciences2.4337 of 5 stars$7.07-8.2%$16.00+126.3%N/A$251.23MN/A-0.2320Positive NewsTNXPTonix Pharmaceuticals3.4974 of 5 stars$27.75-3.0%$70.00+152.3%+82.4%$250.79M$10.09M-0.7050Analyst RevisionALLOAllogene Therapeutics3.2436 of 5 stars$1.15+1.8%$8.44+634.3%-54.2%$250.73MN/A-1.04310Positive News Related Companies and Tools Related Companies NGNE Alternatives DBVT Alternatives RAPT Alternatives ANNX Alternatives CADL Alternatives NMRA Alternatives RNAC Alternatives JBIO Alternatives TNXP Alternatives ALLO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:VNRX) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNRX Stock Alerts